Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ImmunoGen Inc

Healthcare US IMGN

NoneUSD
0.00(0%)

Last update at 2024-03-07T21:02:38.223035Z

Day Range

--
LowHigh

52 Week Range

3.6029.96
LowHigh

Fundamentals

  • Previous Close 31.23
  • Market Cap7992.39M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield1.13%
  • EBITDA-78.45900M
  • Revenue TTM287.61M
  • Revenue Per Share TTM1.09
  • Gross Profit TTM -104.76400M
  • Diluted EPS TTM-0.28

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -221.71100M -139.30300M -44.37200M -104.13300M -167.87300M
Minority interest - - - - -
Net income -222.92900M -149.35600M -66.68300M -122.09300M -167.87300M
Selling general administrative 116.13M 43.81M 38.60M 38.49M 36.72M
Selling and marketing expenses - - - - -
Gross profit 108.61M 69.86M 17.71M -32.25100M -120.07000M
Reconciled depreciation 1.78M 2.02M 2.10M 4.03M 7.41M
Ebit -220.89300M -125.07300M -135.48500M -92.17300M -160.86500M
Ebitda -217.54600M -126.15300M -19.68300M -65.72600M -153.45400M
Depreciation and amortization 3.35M -1.08000M 115.80M 26.45M 7.41M
Non operating income net other 3.35M -1.08000M 1.21M 5.01M 3.33M
Operating income -220.89300M -125.07300M -135.48500M -92.17300M -160.47900M
Other operating expenses 329.68M 194.93M 153.19M 153.01M 210.60M
Interest expense 4.17M 13.15M 23.20M 16.97M 10.73M
Tax provision 1.22M - - - -
Interest income - - - 12.55M 4.90M
Net interest income -4.16500M -13.15000M -23.20200M -16.97400M -10.72600M
Extraordinary items - - - - -
Non recurring - - 1.49M 21.43M 3.69M
Other items - - - - -
Income tax expense 1.22M 10.05M 22.31M 17.96M 7.39M
Total revenue 108.78M 69.86M 132.30M 82.27M 53.82M
Total operating expenses 329.50M 194.93M 153.19M 153.01M 210.60M
Cost of revenue 0.18M - 114.59M 114.52M 173.89M
Total other income expense net -0.81800M -14.23000M 91.11M -11.96000M -0.36100M
Discontinued operations - - - - -
Net income from continuing ops -222.92900M -139.30300M -21.26500M -87.25400M -158.21200M
Net income applicable to common shares -222.92900M -139.30300M -44.37200M -104.13300M -168.84300M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 348.94M 525.76M 355.07M 235.66M 295.75M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 11.01M 7.32M 7.90M 5.42M 4.46M
Total liab 193.11M 200.18M 265.50M 311.78M 283.81M
Total stockholder equity 155.83M 325.59M 89.57M -76.12100M 11.94M
Deferred long term liab - - - - 4.67M
Other current liab 58.55M 34.62M 78.30M 64.20M 69.74M
Common stock 2.26M 2.20M 1.95M 1.50M 1.49M
Capital stock 2.26M 2.20M 1.95M 1.50M 1.49M
Retained earnings -1694.07200M -1471.14300M -1331.84000M -1287.46800M -1183.33500M
Other liab 60.10M 99.23M 143.18M 210.10M 211.69M
Good will - - - - -
Other assets 30.21M 47.02M 25.06M 3.78M 3.71M
Cash 275.14M 478.75M 293.86M 176.22M 262.25M
Cash and equivalents - - - - -
Total current liabilities 121.86M 100.94M 122.32M 77.41M 70.06M
Current deferred revenue 13.86M 44.35M 29.25M 0.31M 0.32M
Net debt -259.89400M -459.96900M -269.96600M -149.37800M -260.18800M
Short term debt 4.10M 3.54M 5.24M 2.97M -11.36500M
Short long term debt - - 2.09M - -
Short long term debt total 15.24M 18.78M 23.89M 26.85M 2.06M
Other stockholder equity 1847.64M 1794.53M 1419.46M 1209.85M 1232.32M
Property plant equipment 20.57M 17.05M 5.76M 6.99M 12.89M
Total current assets 275.14M 478.75M 293.86M 176.22M 262.25M
Long term investments - - - - -
Net tangible assets 155.83M 325.59M 89.57M -76.12100M 10.97M
Short term investments - - - - -
Net receivables 17.98M 13.93M 22.50M 27.25M 12.07M
Long term debt - - - 2.08M 2.06M
Inventory 16.20M -21.24900M -30.39800M -32.67300M -16.52900M
Accounts payable 45.35M 18.43M 9.54M 9.93M 11.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -32.46600M -39.50400M
Additional paid in capital - - - - -
Common stock total equity 2.26M 2.20M 1.95M 1.50M 1.49M
Preferred stock total equity - - - - -
Retained earnings total equity -1694.07200M -1471.14300M -1331.84000M -1287.46800M -1183.33500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 59.19M 29.96M 41.38M 36.86M 20.61M
Deferred long term asset charges - - - - -
Non current assets total 73.80M 47.02M 61.22M 59.44M 33.50M
Capital lease obligations 15.24M 18.78M 21.80M 24.77M -
Long term debt total - - - 2.08M 2.06M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.36400M -1.43400M 0.51M -0.53300M -5.24600M
Change to liabilities 47.13M -8.89300M 11.81M -9.38000M 6.83M
Total cashflows from investing activities -1.36400M -1.43400M 0.51M -0.53300M -5.24600M
Net borrowings - -1.10000M -1.10000M -1.10000M -1.10000M
Total cash from financing activities 27.55M 355.74M 195.74M 2.87M 166.81M
Change to operating activities 10.03M -4.89400M 1.50M -10.54700M 2.75M
Net income -222.92900M -139.30300M -44.37200M -104.13300M -168.84300M
Change in cash -203.61200M 184.89M 117.63M -86.02700M -4.85500M
Begin period cash flow 478.75M 293.86M 176.22M 262.25M 267.11M
End period cash flow 275.14M 478.75M 293.86M 176.22M 262.25M
Total cash from operating activities -229.80200M -169.41600M -78.62000M -88.36700M -166.42200M
Issuance of capital stock 25.65M 154.03M 194.27M 0.00000M 162.51M
Depreciation 1.78M 2.02M 2.10M 4.03M 7.41M
Other cashflows from investing activities - - 1.43M 2.31M -
Dividends paid - - - - -
Change to inventory -16.19600M -11.07700M 10.22M -11.87300M 1.04M
Change to account receivables -8.12900M -4.43200M 7.46M -5.79900M 0.95M
Sale purchase of stock 27.55M 356.84M 195.74M 2.87M 166.81M
Other cashflows from financing activities 1.91M 202.81M 1.47M -0.53300M 4.30M
Change to netincome 12.78M -8.57700M -54.89900M -31.55900M -15.23200M
Capital expenditures 1.36M 1.43M 0.92M 2.85M 5.25M
Change receivables -8.12900M -4.43200M 7.46M -5.79900M 0.95M
Cash flows other operating -44.23700M -8.75400M -0.73000M 58.48M 1.43M
Exchange rate changes - - - - -
Cash and cash equivalents changes -203.61200M 184.89M 117.63M -86.02700M -4.85500M
Change in working capital -25.60000M -23.55300M -4.55700M 25.72M -0.29400M
Stock based compensation 25.61M 17.48M 14.32M 14.17M 16.81M
Other non cash items -8.67100M -26.05200M -45.42200M -30.53600M -21.61800M
Free cash flow -231.16600M -170.85000M -79.53700M -91.21200M -171.66800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMGN
ImmunoGen Inc		 - -% - - 147.06 27.43 14.05 25.62 -120.7063
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

ImmunoGen Inc

830 Winter Street, Waltham, MA, United States, 02451-1477

Key Executives

Name Title Year Born
Mr. Mark Joseph Enyedy Pres, CEO & Director 1964
Ms. Susan Altschuller Ph.D. Sr. VP & CFO 1983
Dr. Anna Berkenblit M.D., MM.Sc Sr. VP & Chief Medical Officer 1970
Ms. Stacy A. Coen Sr. VP & Chief Bus. Officer 1971
Ms. Renee Lentini VP of Fin. & Principal Accounting Officer 1978
Ms. Courtney O'Konek Sr. Director of Corp. Communications & Investor Relations NA
Mr. Daniel S. Char J.D. Sr. VP & Chief Legal Officer 1961
Ms. Audrey Bergan Sr. VP & Chief HR Officer NA
Dr. Theresa G. Wingrove Sr. VP of Regulatory Affairs & Quality 1958
Dr. Mary Margaret Huizinga FACP, M.D., M.P.H. Sr. VP & Head of Medical Affairs 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions